Shared on14 Sep 25Fair value Increased 2.14%
The recent upward revision in Everest Medicines’ consensus Analyst Price Target is primarily driven by a modest increase in its expected future P/E multiple, lifting fair value from HK$61.36 to HK$62.67. What's in the News Everest Medicines expects 2025 revenue of RMB 1.6–1.8 billion, with NEFECON sales contributing RMB 1.2–1.4 billion.
Shared on31 Aug 25Fair value Increased 11%
The notable increase in Everest Medicines’ consensus price target reflects a significant improvement in net profit margin alongside a sharp decline in future P/E, indicating enhanced profitability and a more attractive valuation, with the target rising to HK$57.29. What's in the News The board will meet to discuss interim results for the first half of 2025 and other business.